Johnson & Johnson (JNJ): Total Assets
$199.21B
As of 2025-12-28
$197.43B
As of 2026-09-27
+2.1%
3-year compound annual growth
+2.6%
5-year compound annual growth
+4.1%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | $199.21B | +10.6% | 2026-02-11, Balance as of period end |
| 2024-12-29 | $180.10B | +7.5% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $167.56B | -10.6% | 2025-02-13, Balance as of period end |
| 2023-01-01, Fiscal 2022 | $187.38B | +2.9% | 2024-02-16, Balance as of period end |
| 2022-01-02, Fiscal 2021 | $182.02B | +4.1% | 2023-02-16, Balance as of period end |
| 2021-01-03, Fiscal 2020 | $174.89B | +10.9% | 2022-02-17, Balance as of period end |
| 2019-12-29 | $157.73B | +3.1% | 2021-02-22, Balance as of period end |
| 2018-12-30 | $152.95B | -2.8% | 2020-02-18, Balance as of period end |
| 2017-12-31 | $157.30B | +11.4% | 2019-02-20, Balance as of period end |
| 2017-01-01, Fiscal 2016 | $141.21B | +5.8% | 2018-02-21, Balance as of period end |
| 2016-01-03, Fiscal 2015 | $133.41B | +2.3% | 2017-02-27, Balance as of period end |
| 2014-12-28 | $130.36B | -1.8% | 2016-02-24, Balance as of period end |
| 2013-12-29 | $132.68B | +9.3% | 2015-02-24, Balance as of period end |
| 2012-12-30 | $121.35B | +6.8% | 2015-02-24, Balance as of period end |
| 2012-01-01, Fiscal 2011 | $113.64B | +10.4% | 2014-02-21, Balance as of period end |
| 2011-01-02, Fiscal 2010 | $102.91B | +8.7% | 2013-02-22, Balance as of period end |
| 2010-01-03, Fiscal 2009 | $94.68B | +11.5% | 2012-02-23, Balance as of period end |
| 2008-12-28 | $84.91B | n/a | 2011-02-25, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $133.96B | -0.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $40.75B | +3.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $40.56B | +7.4% |
Compare JNJ, LLY, MRK, PFE side by side · Screen every company in Pharmaceutical Preparations ↗